ArticleClinical and translational science2023

Safety and tolerability of a 90-minute rapid infusion of Sandoz biosimilar rituximab in B-cell lymphoproliferative disorders in a real-world setting.

Ana Muntañola et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.